A Multi-center Prospective Randomized Phase III Trial to Determine the Benefit of Adjuvant Chemotherapy Using Gemcitabine and Cisplatin in Nasopharyngeal Carcinoma Patients With Residual EBV DNA Following Primary Radiotherapy With or Without Concurrent Cisplatin
Overview
- Phase
- Phase 3
- Intervention
- Adjuvant chemotherapy (gemcitabine and cisplatin)
- Conditions
- Nasopharyngeal Cancer
- Sponsor
- Chinese University of Hong Kong
- Enrollment
- 104
- Locations
- 6
- Primary Endpoint
- Relapse free survival
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
The purpose of this trial is to study the benefit of adjuvant chemotherapy using gemcitabine and cisplatin in high risk NPC patients with residual EBV DNA following primary radiotherapy with or without concurrent cisplatin.
Detailed Description
* The standard treatment for nasopharynx cancer is a course of radiotherapy with or without concurrent chemotherapy. This will cure about 80% of patients. For the 20% who developed recurrence or metastases, the prognosis is poor. * Elevated EBV-DNA in plasma at end of radiotherapy has been shown to predict disease recurrence and may be a marker of subclinical residual disease. * This study aims to test whether adjuvant treatment with 6 cycles of a modern chemotherapy regimen (gemcitabine and cisplatin combination) can improve the survival of these high risk patients of nasopharynx cancer who have elevated EBV-DNA after completion of their radiotherapy.
Investigators
Edwin P Hui
Consultant
Chinese University of Hong Kong
Eligibility Criteria
Inclusion Criteria
- •Have given written informed consent, prior to pre-study screening, with the understanding that consent may be withdrawn at any time without prejudice.
- •A histological diagnosis of nasopharyngeal cancer (NPC) must have been established at some time and the investigator must review and confirm the diagnosis prior to randomization.
- •Loco-regional advanced NPC UICC/AJCC Stages IIB, III, IVA or IVB.
- •No evidence of distant metastases in the staging work up at diagnosis.
- •Must have detectable plasma EBV-DNA (\> 0 copies/ml) at 6-8 weeks after completion of primary RT or chemo-RT
- •No clinical evidence of persistent loco-regional disease after primary treatment
- •Performance status of ECOG grade 0 or
- •Patients must have adequate organ and marrow function as defined below:
- •leukocytes \>3,000/L; absolute neutrophil count \>1,500/L; platelets \>100,000/L; total bilirubin \<1.5 X institutional upper limit of normal; AST(SGOT)/ALT(SGPT) \<2.5 X institutional upper limit of normal; Creatinine clearance \> 50 ml/min
- •At least 18 years of age, of either sex.
Exclusion Criteria
- •Hypercalcaemia: calcium \>= 2.7 mmol/L (10.8 mg/dL).
- •Second primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin).
- •More that 12 weeks after completion of primary radiotherapy.
- •Had received prior adjuvant chemotherapy.
- •Other serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator).
- •Have serious active infection.
- •Patients with peripheral or ototoxicity with a grade of greater than
- •Pregnant or lactating female subjects and subjects with reproductive potential not implementing adequate contraceptive measures.
Arms & Interventions
A
Adjuvant chemotherapy and then clinical follow-up and surveillance
Intervention: Adjuvant chemotherapy (gemcitabine and cisplatin)
Outcomes
Primary Outcomes
Relapse free survival
Time Frame: 5 years
Secondary Outcomes
- Correlation of plasma EBV DNA and PET/CT scan with clinical course and outcome(5 years)
- Overall survival(5 years)
- Loco-regional control(5 years)
- Metastasis-free survival(5 years)
- Toxicity of adjuvant chemotherapy(6 months)